A Phase 3 interventional study of Lurasidone in Major Depressive Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-08.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 801st largest by enrollment of the 1,323 interventional ones that give a count, is one of 84 that started in 2011, is one of 240 in phase 3, and was the 506th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 84 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
Sumitomo Pharma Co., Ltd. has 5 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject provides written and is willing and able to comply with the protocol in the opinion of the Investigator.
Subject has completed 6 weeks of treatment in Study D1050304 (NCT#01421134) or Study D1050305 (NCT#01423240).
Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator.
Exclusion Criteria:
Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at baseline (Day 43 in Study D1050304 or D1050305).
Subject is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone 20, 40, or 60 mg/day flexibly dosed
Drug: Lurasidone
Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
Also known as: Latuda
Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)
Percentage of subjects with treatment emergent adverse events (TEAEs)
Time frame: 12 Weeks
Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs)
Percentage of subjects with Treatment Emergent Serious Adverse Events (TESAEs)
Time frame: 12 Weeks
Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs)
Percentage of subjects who discontinued due to Treatment Emergent Adverse Events (TEAEs)
Time frame: 12 Weeks
Mean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores
Mean change from baseline to week 12 (LOCF) in Montgomery-Asberg Depression Rating Scale (MADRS) total scores The MADRS is a clinician-rated assessment of the subject's level of depression and consists of 10 items. Each item is rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the ten items and ranges from 0 to 60. Higher scores are associated with greater severity.
Time frame: Baseline to12 Weeks
Change From Baseline to Week 12 (LOCF) in CGI-S Score
The Clinical Global Impression - Severity of illness (CGI-S) score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
Time frame: baseline to week 12
Change From Baseline to Week 12 (LOCF) in the YMRS Total Score
The Young Mania Rating Scale (YMRS) is an 11-item instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.
Time frame: Baseline to week 12
Change From Baseline to Week 12 (LOCF) in the HAM-A Total Score
The Hamilton Rating Scale for Anxiety (HAM-A) is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.
Time frame: Baseline to week 12
Change From Baseline to Week 12 (LOCF) in the SDS Total Score
The Sheehan Disability Scale (SDS) is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).
Time frame: Baseline to week 12
| Milestone | Lurasidone 20, 40, 60 mg |
|---|---|
| Started | 48 |
| Completed | 39 |
| Not completed | 9 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 2 |
Percentage of subjects with treatment emergent adverse events (TEAEs)
| percentage of subjects | Lurasidone 20, 40, 60 mg |
|---|---|
| Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) | 66.7 |
Mean change from baseline to week 12 (LOCF) in Montgomery-Asberg Depression Rating Scale (MADRS) total scores The MADRS is a clinician-rated assessment of the subject's level of depression and consists of 10 items. Each item is rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the ten items and ranges from 0 to 60. Higher scores are associated with greater severity.
| units on a scale | Lurasidone 20, 40, 60 mg |
|---|---|
| Mean Change From Baseline to Week 12 (LOCF) in MADRS Total Scores | -5.9 ± 12.94 |
Percentage of subjects with Treatment Emergent Serious Adverse Events (TESAEs)
| percentage of subjects | Lurasidone 20, 40, 60 mg |
|---|---|
| Percentage of Subjects With Treatment Emergent Serious Adverse Events (TESAEs) | 0 |
Percentage of subjects who discontinued due to Treatment Emergent Adverse Events (TEAEs)
| percentage of subjects | Lurasidone 20, 40, 60 mg |
|---|---|
| Percentage of Subjects Who Discontinued Due to Treatment Emergent Adverse Events (TEAEs) | 4.2 |
The Clinical Global Impression - Severity of illness (CGI-S) score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.
| units on a scale | Lurasidone 20, 40, 60 mg |
|---|---|
| Change From Baseline to Week 12 (LOCF) in CGI-S Score | -0.47 ± 1.442 |
The Young Mania Rating Scale (YMRS) is an 11-item instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.
| units on a scale | Lurasidone 20, 40, 60 mg |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the YMRS Total Score | -1.5 ± 6.17 |
The Hamilton Rating Scale for Anxiety (HAM-A) is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.
| units on a scale | Lurasidone 20, 40, 60 mg |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the HAM-A Total Score | -1.5 ± 6.48 |
The Sheehan Disability Scale (SDS) is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).
| units on a scale | Lurasidone 20, 40, 60 mg |
|---|---|
| Change From Baseline to Week 12 (LOCF) in the SDS Total Score | -3.6 ± 9.95 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 20, 40, 60 mg | — | 0/48 (0%) | 16/48 (33.3%) |
| Event | Lurasidone 20, 40, 60 mg |
|---|---|
| AkathisiaNervous system disorders | 5/48 |
| DiarrhoeaGastrointestinal disorders | 4/48 |
| Upper respiratory tract infectionInfections and infestations | 4/48 |
| NauseaGastrointestinal disorders | 3/48 |
| FatigueGeneral disorders | 3/48 |
| HeadacheNervous system disorders | 3/48 |
| SedationNervous system disorders | 3/48 |
Safety population
| Age, Categorical(Participants) | Lurasidone 20, 40, 60 mg |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 45 |
| >=65 years | 2 |
| Age, Continuous(Years) | Lurasidone 20, 40, 60 mg |
|---|---|
| Mean | 42.5 ± 13.42 |
| Sex: Female, Male(Participants) | Lurasidone 20, 40, 60 mg |
|---|---|
| Female | 36 |
| Male | 12 |
| Race (NIH/OMB)(Participants) | Lurasidone 20, 40, 60 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 21 |
| White | 24 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | Lurasidone 20, 40, 60 mg |
|---|---|
| United States | 48 |
The record gives a start of Sep 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 2 years after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →